Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial.
Publication/Presentation Date
3-1-2021
Abstract
Recognizing that body surface area (BSA) is a commonly used metric to inform medication dosing across fields of medicine, it is possible that patients with heart failure with reduced ejection fraction (HFrEF) with higher BSA may be more likely to tolerate higher doses of GDMT. Using the HF-ACTION trial, we examined (1) the relationship between BSA and achievement of target dosing of evidence-based beta-blocker and angiotensin-converting enzyme inhibitor (ACEI) therapy, and (2) the associations and interactions between target dosing, clinical outcomes, and BSA.
Volume
233
First Page
1
Last Page
4
ISSN
1097-6744
Published In/Presented At
Brooksbank, J. A., Greene, S. J., Harris, H. M., Stebbins, A., Fiuzat, M., Whellan, D. J., Alhanti, B., Kraus, W. E., Piña, I. L., O'Connor, C. M., & Mentz, R. J. (2021). Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. American heart journal, 233, 1–4. https://doi.org/10.1016/j.ahj.2020.11.003
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
33245905
Department(s)
Administration and Leadership
Document Type
Article